Description
ADCC-Enhanced anti-CD80 (L104EA29YIg) is a non-fucosylated therapeutic biobetter antibody engineered by Creative Biolabs' Afuco™ technology platform.
Antibody Indication
Immune System Diseases
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced CD80 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
CD80
Full Name
CD80 molecule
Background
The protein encoded by this gene is a membrane receptor that is activated by the binding of CD28 or CTLA-4. The activated protein induces T-cell proliferation and cytokine production. This protein can act as a receptor for adenovirus subgroup B and may play a role in lupus neuropathy.
Alternative Names
CD80; CD80 molecule; B7; BB1; B7-1; B7.1; LAB7; CD28LG; CD28LG1; T-lymphocyte activation antigen CD80; activation B7-1 antigen; costimulatory factor CD80; CTLA-4 counter-receptor B7.1; B-lymphocyte activation antigen B7; costimulatory molecule variant IgV-CD80; CD80 antigen (CD28 antigen ligand 1, B7-1 antigen)
Gene ID
941
UniProt ID
Q5ZPR3
Cellular Localization
Membrane
Involvement in Disease
Diseases associated with CD80 include Vaccinia and Focal Segmental Glomerulosclerosis.
Related Pathways
Its related pathways are Nur77 Signaling in T-Cell and RET signaling. Gene Ontology (GO) annotations related to this gene include coreceptor activity.
Function
Participate in the costimulatory signals necessary for T lymphocyte activation. CD28 binding induces T cell proliferation and cytokine production, while binding to CTLA-4 has the opposite effect and inhibits T cell activation. (Microbial infection) As a receptor for adenovirus B subgroup.
Field of research
Developmental Biology antibody; Immune System antibody
Post-translational modifications
1.Glycosylation at Asn53, Asn89, Asn98, Asn186, Asn207, Asn211, Asn226, and Asn232 2.Modification sites at PhosphoSitePlus
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
L104EA29YIg
Description
The binding of L104EA29YIg to CD86 or CD80 can be used to treat immune system diseases such as graft rejection following organ transplant.
Antibody Indication
Immune System Diseases
